Kindred BioSciences Inc. – Nasdaq: KIN
Kindred BioSciences Inc. is a biotechnology firm that leverages the R&D funding of human pharmaceuticals by re-purposing existing human drugs for the pet market. Traded on the Nasdaq under ticker KIN, the shares are trading, on heavy volume, today at their highest point in over a year – $6.30.
Based in Burlingame, CA, Kindred Bioscience’s stated mission is to bring pets the same kind of innovative, breakthrough medicines that humans have access to. Kindred Bioscience is one of the first pet biotechs in the world, and has a world-class team, including the former Director of FDA’s Center for Veterinary Medicine and the former Head of Biotherapeutics Clinical Research at Genentech. They hope to arbitrage the differences in the market size for human pharmaceuticals (about 10 times larger than for pets) and the expense for developing those pharmaceuticals (about 100 times less).
Kindred Biosciences has no reported sales and KIN has never experienced positive EPS. However, KIN is rated as a “Strong Buy” by the only two analysts that cover the shares.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 12:27 PM EST||$ 6.23|
|Market Cap||$113.5 million|
|Shares Outstanding||19.74 million|
|Share Float||17.17 million|
|Short Interest Ratio||0.48|